Impact of Etanercept on Vitamin D Status and Vitamin D-binding Protein in Bio-naïve Patients with Psoriasis


  • Maria Siekkeri Vandikas Dermatology and Venereology Unit, Karolinska University Hospital, Solna, Eugeniavägen 3, A6:01, SE-171 76, Stockholm, Sweden
  • Kerstin Landin-Wilhelmsen
  • Sam Polesie
  • Martin Gillstedt
  • Amra Osmancevic



psoriasis, psoriatic arthritis, tumour necrosis factor inhibitor, vitamin D, vitamin D-binding protein, biomarker


High levels of serum vitamin D-binding protein have been shown previously in patients with psoriasis compared with healthy controls; a possible role in inflammation is implied. The primary objective of this study was to investigate the impact of 24-week etanercept treatment on vitamin D status and vitamin D-binding protein in patients with psoriasis. The secondary aim was to explore whether pre-treatment vitamin D levels could predict the treatment effect. A prospective observational study was performed, including 20 patients with psoriasis and 15 controls. Serum samples were analyzed for, among others, vitamin D metabolites, vitamin D-binding protein and highly sensitive C-reactive protein. Baseline levels of vitamin D-binding protein were higher in patients with self-reported arthropathy than in those without. After 24 weeks’ treatment, an improvement in psoriasis was noted, as was a decrease in highly sensitive C-reactive protein. Vitamin D-binding protein decreased in those with self-reported arthropathy. Higher baseline levels of vitamin D were associated with faster and greater improvement in psoriasis. Vitamin D-binding protein may have an inflammatory biomarker role.


Download data is not yet available.


Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 2020; 323: 1945-1960. DOI:

Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017; 76: 377-390. DOI:

Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol 2016; 38: 11-27. DOI:

Hambly R, Kirby B. The relevance of serum vitamin D in psoriasis: a review. Arch Dermatol Res 2017; 309: 499-517. DOI:

Barrea L, Savanelli MC, Di Somma C, Napolitano M, Megna M, Colao A, et al. Vitamin D and its role in psoriasis: an overview of the dermatologist and nutritionist. Rev Endocr Metab Disord 2017; 18: 195-205. DOI:

Kuo YT, Kuo CH, Lam KP, Chu YT, Wang WL, Huang CH, et al. Effects of vitamin D3 on expression of tumor necrosis factor-alpha and chemokines by monocytes. J Food Sci 2010; 75: H200-H204. DOI:

Stio M, Martinesi M, Bruni S, Treves C, d'Albasio G, Bagnoli S, et al. Interaction among vitamin D(3) analogue KH 1060, TNF-alpha, and vitamin D receptor protein in peripheral blood mononuclear cells of inflammatory bowel disease patients. Int Immunopharmacol 2006; 6: 1083-1092. DOI:

Inanir A, Ozoran K, Tutkak H, Mermerci B. The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis. J Int Med Res 2004; 32: 570-582. DOI:

van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Cornelissen F, van Leeuwen JP, et al. TNF blockade requires 1,25(OH)2D3 to control human Th17-mediated synovial inflammation. Ann Rheum Dis 2012; 71: 606-612. DOI:

Dankers W, González-Leal C, Davelaar N, Asmawidjaja PS, Mus AMC, Hazes JMW, et al. 1,25(OH)(2)D(3) and dexamethasone additively suppress synovial fibroblast activation by CCR6(+) T helper memory cells and enhance the effect of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018; 20: 212. DOI:

Winter RW, Collins E, Cao B, Carrellas M, Crowell AM, Korzenik JR. Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases. Aliment Pharmacol Ther 2017; 45: 653-659. DOI:

Martinez-Lopez A, Blasco-Morente G, Giron-Prieto MS, Arrabal-Polo MA, Luque-Valenzuela M, Luna-Del Castillo JD, et al. Linking of psoriasis with osteopenia and osteoporosis: a cross-sectional study. Indian J Dermatol Venereol Leprol 2019; 85: 153-159. DOI:

Bouillon R, Schuit F, Antonio L, Rastinejad F. Vitamin D binding protein: a historic overview. Front Endocrinol 2020; 10: 910. DOI:

Chun RF, Shieh A, Gottlieb C, Yacoubian V, Wang J, Hewison M, et al. Vitamin D binding protein and the biological activity of vitamin D. Front Endocrinol (Lausanne) 2019; 10: 718. DOI:

Guha C, Osawa M, Werner PA, Galbraith RM, Paddock GV. Regulation of human Gc (vitamin D-binding) protein levels: hormonal and cytokine control of gene expression in vitro. Hepatology (Baltimore, MD) 1995; 21: 1675-1681. DOI: DOI:

Delanghe JR, Speeckaert R, Speeckaert MM. Behind the scenes of vitamin D binding protein: more than vitamin D binding. Best Pract Res Clin Endocrinol Metab 2015; 29: 773-786. DOI:

Kongsbak M, von Essen MR, Levring TB, Schjerling P, Woetmann A, Ødum N, et al. Vitamin D-binding protein controls T cell responses to vitamin D. BMC Immunol 2014; 15: 35-35. DOI:

Jeffery LE, Wood AM, Qureshi OS, Hou TZ, Gardner D, Briggs Z, et al. Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. J Immunol 2012; 189: 5155-5164. DOI:

Speeckaert MM, Speeckaert R, van Geel N, Delanghe JR. Vitamin D binding protein: a multifunctional protein of clinical importance. Adv Clin Chem 2014; 63: 1-57. DOI:

Oleröd G, Hultén LM, Hammarsten O, Klingberg E. The variation in free 25-hydroxy vitamin D and vitamin D-binding protein with season and vitamin D status. Endocrine Connections 2017; 6: 111-120. DOI:

Vandikas MS, Landin-Wilhelmsen K, Holmäng A, Gillstedt M, Osmancevic A. High levels of serum vitamin D-binding protein in patients with psoriasis: a case-control study and effects of ultraviolet B phototherapy. J Steroid Biochem Mol Biol 2021; 211: 105895. DOI:

Flytström I, Stenberg B, Svensson Å, Bergbrant IM. Patients' visual analogue scale: a useful method for assessing psoriasis severity. Acta Derm Venereol 2012; 92: 347-348. DOI:

Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124: 869-871. DOI: DOI:

Zator ZA, Cantu SM, Konijeti GG, Nguyen DD, Sauk J, Yajnik V, et al. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-α therapy in inflammatory bowel diseases. JPEN J Parenter Enteral Nutr 2014; 38: 385-391. DOI:

Bafutto M, Oliveira EC, Rezende Filho J. Use of vitamin D with anti-tumor necrosis factor therapy for Crohn's disease. Gastroenterology Res 2020; 13: 101-106. DOI:

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930. DOI:

Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 1986; 63: 954-959. DOI:

Welsh P, Peters MJ, McInnes IB, Lems WF, Lips PT, McKellar G, et al. Vitamin D deficiency is common in patients with RA and linked to disease activity, but circulating levels are unaffected by TNFα blockade: results from a prospective cohort study. Ann Rheum Dis 2011; 70: 1165-1167. DOI:

Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341-344. DOI:

Ganzetti G, Campanati A, Scocco V, Brugia M, Tocchini M, Liberati G, et al. The potential effect of the tumour necrosis factor-α inhibitors on vitamin D status in psoriatic patients. Acta Derm Venereol 2014; 94: 715-717. DOI:

Yousefzadeh P, Shapses SA, Wang X. Vitamin D binding protein impact on 25-hydroxyvitamin D levels under different physiologic and pathologic conditions. Int J Endocrinol 2014; 2014: 981581. DOI:

Ekman AK, Sigurdardottir G, Carlstrom M, Kartul N, Jenmalm MC, Enerback C. Systemically elevated Th1-, Th2- and Th17-associated chemokines in psoriasis vulgaris before and after ultraviolet B treatment. Acta Derm Venereol 2013; 93: 527-531. DOI:

Sigurdardottir G, Ekman AK, Stahle M, Bivik C, Enerback C. Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis. J Am Acad Dermatol 2014; 70: 1067-1075. DOI:

Robinson-Cohen C, Zelnick LR, Hoofnagle AN, Lutsey PL, Burke G, Michos ED, et al. Associations of vitamin D-binding globulin and bioavailable vitamin D concentrations with coronary heart disease events: the multi-ethnic study of atherosclerosis (MESA). J Clin Endocrinol Metab 2017; 102: 3075-3084. DOI:

Lai YC, Yew YW. Psoriasis as an independent risk factor for cardiovascular disease: an epidemiologic analysis using a national database. J Cutan Med Surg 2016; 20: 327-333. DOI:

Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol 2018; 9: 579. DOI:

Ghaly S, Murray K, Baird A, Martin K, Prosser R, Mill J, et al. High vitamin D-binding protein concentration, low albumin, and mode of remission predict relapse in Crohn's disease. Inflamm Bowel Dis 2016; 22: 2456-2464. DOI:

Srikanth P, Chun RF, Hewison M, Adams JS, Bouillon R, Vanderschueren D, et al. Associations of total and free 25OHD and 1,25(OH)2D with serum markers of inflammation in older men. Osteoporos Int 2016; 27: 2291-2300. DOI:

Augustine MV, Leonard MB, Thayu M, Baldassano RN, de Boer IH, Shults J, et al. Changes in vitamin D-related mineral metabolism after induction with anti-tumor necrosis factor-α therapy in Crohn's disease. J Clin Endocrinol Metab 2014; 99: E991-E998. DOI:

Adami G, Orsolini G, Adami S, Viapiana O, Idolazzi L, Gatti D, et al. Effects of TNF inhibitors on parathyroid hormone and Wnt signaling antagonists in rheumatoid arthritis. Calcif Tissue Int 2016; 99: 360-364. DOI:

Arques S. Human serum albumin in cardiovascular diseases. Eur J Intern Med 2018; 52: 8-12. DOI:

Kirmit A, Kader S, Aksoy M, Bal C, Nural C, Aslan O. Trace elements and oxidative stress status in patients with psoriasis. Postepy Dermatol Alergol 2020; 37: 333-339. DOI:

Mechie NC, Mavropoulou E, Ellenrieder V, Kunsch S, Cameron S, Amanzada A. Distinct association of serum vitamin D concentration with disease activity and trough levels of infliximab and adalimumab during inflammatory bowel disease treatment. Digestion 2020; 101: 761-770. DOI:

Hlavaty T, Krajcovicova A, Koller T, Toth J, Nevidanska M, Huorka M, et al. Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases. World J Gastroenterol 2014; 20: 15787-15796. DOI:

Batista MC, Menegat FD, Ferreira CES, Faulhaber ACL, Campos D, Mangueira CLP. Analytical and clinical validation of the new Roche Elecsys Vitamin D Total II assay. Clin Chem Lab Med 2018; 56: e298-e301. DOI:




How to Cite

Vandikas, M. S., Landin-Wilhelmsen, K., Polesie, S., Gillstedt, M., & Osmancevic, A. (2021). Impact of Etanercept on Vitamin D Status and Vitamin D-binding Protein in Bio-naïve Patients with Psoriasis. Acta Dermato-Venereologica, 101(11), adv00604.